| Phase II study of induction platinum doublet in combination with nivolumab followed by surgery or concurrent chemotherapy-nivolumab-radiation in unresectable stage IIIA-C non … R Zinner, SL Meyerson, RC McGarry, TW Mullett, JL Villano, Z Hao, ... Journal of Clinical Oncology 42 (16_suppl), TPS8122-TPS8122, 2024 | | 2024 |
| Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia OA Elgamal, S Fobare, S Vibhute, A Mehmood, DC Vroom, ML Johnson, ... JCI insight 9 (8), 2024 | | 2024 |
| Final survival outcomes and post-hoc tumor gene expression pathway analyses of complete responders from a phase Ib clinical trial of HSP90 inhibitor onalespib and paclitaxel in … DM Quiroga, H Savardekar, E Schwarz, NO Williams, C Johnson, ... Cancer Research 84 (6_Supplement), 7632-7632, 2024 | | 2024 |
| RNA four-way junction (4WJ) for spontaneous cancer-targeting, effective tumor-regression, metastasis suppression, fast renal excretion and undetectable toxicity X Li, K Jin, TC Cheng, YC Liao, WJ Lee, AS Bhullar, LC Chen, ... Biomaterials 305, 122432, 2024 | 5 | 2024 |
| Antibody drug clearance: an underexplored marker of outcomes with checkpoint inhibitors Y Guo, BC Remaily, J Thomas, K Kim, SK Kulp, TA Mace, LP Ganesan, ... Clinical Cancer Research 30 (5), 942-958, 2024 | | 2024 |
| The effects of food on the pharmacokinetics of mycophenolate mofetil in healthy horses K Bello, G Lorch, MG Papich, K Kim, RE Toribio, L Yan, Z Xie, K Hill, ... Journal of Veterinary Pharmacology and Therapeutics, 2024 | | 2024 |
| Mymel: A Phase 1 Trial of AUC-Targeted High Dose Melphalan in Multiple Myeloma Patients Undergoing Autologous Transplant K Sweiss, K Kim, J Guo, K Hill, N Abbott, ME Sanchez, C Uzoka, J Quigley, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | | 2024 |
| Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial M Lustberg, P Fan-Havard, FL Wong, K Hill, MA Phelps, KW Herrera, ... Breast cancer research and treatment, 1-13, 2024 | | 2024 |
| A phase I clinical trial of riluzole in combination with mFOLFOX6 and bevacizumab in treating patients with metastatic colorectal cancer. C Li, AM Noonan, JL Hays, S Roychowdhury, PG Malalur, RT Elkhatib, ... Journal of Clinical Oncology 42 (3_suppl), 101-101, 2024 | | 2024 |
| In Vitro and In Vivo Evaluation of the Pathology and Safety Aspects of Three- and Four-Way Junction RNA Nanoparticles K Jin, YC Liao, TC Cheng, X Li, WJ Lee, F Pi, D Jasinski, LC Chen, ... Molecular Pharmaceutics 21 (2), 718-728, 2024 | 3 | 2024 |
| CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation ND Seligson, X Zhang, MC Zemanek, JA Johnson, Z VanGundy, D Wang, ... Frontiers in Pharmacology 14, 1334440, 2024 | 1 | 2024 |
| Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia TT Vu, K Kim, M Manna, J Thomas, BC Remaily, EJ Montgomery, T Costa, ... Pharmacological research 199, 107048, 2024 | 1 | 2024 |
| Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer NO Williams, D Quiroga, C Johnson, A Brufsky, M Chambers, ... Therapeutic Advances in Medical Oncology 15, 17588359231217976, 2023 | | 2023 |
| Correction to: Increased renal elimination of endogenous and synthetic pyrimidine nucleosides in concentrative nucleoside transporter 1 deficient mice (Nature Communications … AK Persaud, MC Bernier, MA Massey, S Agrawal, T Kaur, D Nayak, Z Xie, ... Nature Communications 14 (1), 3335, 2023 | | 2023 |
| RAMP up: Risk Adapted Post-Autologous Transplant Maintenance Therapy in MRD Positive Myeloma Patients K Sweiss, CC Hofmeister, GR Mohyuddin, A Godara, B McClune, ... Blood 142, 4974, 2023 | | 2023 |
| Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia B Bhatnagar, Q Zhao, AS Mims, S Vasu, GK Behbehani, K Larkin, ... Leukemia & Lymphoma 64 (13), 2091-2100, 2023 | 3 | 2023 |
| 746 Cancer cachexia associated Fc receptor expression on leukocytes as potential mechanism of checkpoint inhibitor resistance in patients and in murine cancer models B Remaily, H Lathrop, J Thomas, K Kim, T Vu, C Stanton, M Manna, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399 RD Gentzler, LC Villaruz, JC Rhee, B Horton, J Mock, M Hanley, K Kim, ... The Oncologist 28 (11), 1007-e1107, 2023 | 2 | 2023 |
| Pharmacokinetics and tolerability of multiple‐day oral dosing of mycophenolate mofetil in healthy horses K Bello, G Lorch, K Kim, RE Toribio, L Yan, Z Xie, K Hill, M Phelps Journal of Veterinary Internal Medicine 37 (5), 1907-1916, 2023 | 2 | 2023 |
| MIF targeted neuroprotection through human serum albumin nanoparticle drug delivery T Heisler-Taylor, S Hamadmad, D Martini, Y Jeng, KE Swindle-Reilly, ... Investigative Ophthalmology & Visual Science 64 (8), 2626-2626, 2023 | | 2023 |
john C. ByrdDistinguished University Professor, The Ohio State University在 osumc.edu 的电子邮件经过验证
